ChromaDex announces results from phase II study of NR supplementation

ChromaDex shares results from a milestone phase II clinical study showcasing the promising effects of nicotinamide riboside, NR, supplementation for people with peripheral artery disease. This study was part of the ChromaDex External Research Program, which donated ChromaDex’s patented NR ingredient, Niagen, the most efficient and high-quality NAD+ precursor, for the advancement of this research. As reported in the peer-reviewed journal Nature Communications by a team of scientists led by Dr. Mary M. McDermott, Northwestern University Feinberg School of Medicine, Chicago, results underscored the functional mobility benefits of NR such as an improvement in treadmill walking time and a statistically significant and clinically meaningful improvement in the six-minute walking distance in individuals with PAD.